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Introductionthe last two decades as a new way to treat inherited or acquired diseases, or to confer 28 protection against infectious diseases. Four plasmid DNA (pDNA) biopharmaceuticals 29 have already been licensed for use in the veterinary field which include prophylactic 30 vaccines to prevent West Nile virus infection in horses [1] and hematopoietic necrosis 31 virus infection in farmed salmon [2] , and therapeutic vaccines to treat canine malignant 32 melanoma [3] and reduce fetal loss in swine [4] . In anticipation of future successes and 33 of a growth of the plasmid biopharmaceutical market, a number of researchers in 34 academia and industry have focused their attention on the establishment of efficient and 35 cost-effective manufacturing processes capable of delivering high amounts of high-36 quality pDNA. Key developments include new delivery methods, fermentation 37
strategies, improved media formulations and genetically engineered vectors and 38
Escherichia coli strains [5] [6] [7] [8] . 39 E. coli host strains of the K-12 and B type such as DH5, DH5α, DH10B, 40 MG1655, JM108, JM101 and BL21 have all been used for pDNA production [9] [10] [11] [12] . 41
Strain background and carbon source choice have been identified as two critical 42 elements to consider when engineering new E. coli strains for pDNA production [10] . 43 popular, previous studies have already demonstrated that productivity data obtained 48 from shake flask experiments often fail to predict the outcome of pDNA production in 49 bench-scale bioreactors [12] . This study addresses the challenge of scaling-up pDNAproduction processes on the basis of shake flask experiments. More specifically, we 51 discuss key factors in the control of fermentation that may affect E. coli behavior and 52 the main reasons for the divergence between shake flask and bioreactor data. As model 53 pDNA producers we use MG1655ΔendAΔrecA, a strain with a wild-type genetic 54 background and deletions in the endA and recA genes, and DH5α, a commonly used 55 laboratory strain which is characterized by a highly mutagenized genetic background 56
[10]. 57 58
Material and Methods 59

Strains and plasmids 60
The bacterial strains MG1655ΔendAΔrecA (F were added in the inoculation day. The reactor was inoculated to an initial OD 600 of 0.1 84 using the prepared inoculum. The dissolved oxygen set-point was controlled at 30% 85 using a cascade to agitation (250 rpm to 800 rpm) and air was provided at a flow rate of 86 1 vvm. The pH was controlled at 7.10 using 1 M NaOH and 1 M H 2 SO 4 . Antifoam was 87 manually added as required. Samples were taken periodically from the bioreactor to 88 quantify biomass, glucose, acetate, and pDNA. 89
90
Plasmid DNA quantification 91
Plasmid DNA was quantified from crude alkaline lysates prepared from cell 92 pellets (OD 600nm = 10) using the hydrophobic interaction HPLC method described 93 before by Diogo et al. (2003) [14] . A 15 PHE PE HIC column (4.6mm×10 cm) from GE 94
Healthcare was firstly equilibrated with 1.5 M ammonium sulfate in 10 mM Tris, pH 95 8.0 (1 ml/min). Thirty µL of lysate samples were injected and isocratic elution was 96 performed with the equilibration buffer for 1.4 min and then with 10 mM Tris, pH 8.0 97 buffer for 0.9 min. At 2.3 min, the column was re-equilibrated with 1.5 M ammonium 98 sulfate. Plasmid concentration was determined from a calibration curve (5-100 μg/ml). Once again this could be associated with a lack of control of important parameters in 158 shake flasks, such as pH. 159
The production experiments reported here highlight the scalability issues 160 referred above, indicating clearly that pDNA productivity obtained when growing E. 161 coli strains on glucose in a controlled bioreactor is several fold higher when compared 162 with shake flask productivity ( Table 1 ). The differences can be attributed to a lack of 163 control of specific variables like pH and dissolved oxygen. According to the data 164 obtained in this study (Table 1) , acetate formation is likely to play an important role in 165 the inhibition of pDNA production at small scale (shake flask), when pH control is 166 absent. A previous study has demonstrated that the protonated form of acetate is able to 167 cross the cell membrane and to uncouple the proton motive force at pH values below the 168 pKa of the acid. Moreover, acetate can still be toxic and inhibit biomass formation at 169 neutral pH when high amounts of the acid are accumulated [19] . This phenomenon is 170 also related to the capacity of each cell to metabolize the acetate, since most of the E. 171 coli cultures reutilize acetate when glucose has been consumed. Thus, although thebe advantageous considering the total mass balance of carbon. The lack of control ofdissolved oxygen in shake flasks can also explain the poor performance observed in 176 shake flasks. Obviously, oxygen transfer rate should be controlled during pDNA 177 production in order to maximize biomass formation [20] and volumetric productivity of 178 pDNA. The use of baffled shake flasks could improve oxygen transfer rate of the cell 179 culture and hopefully contribute to a production performance that is closer to the one 180 observed in bioreactors. In addition, recent studies have shown the importance of an 181 optimal growth rate to increase pDNA yields [21] . 
